Os Agonistas Dopaminérgicos e a Qualidade de Vida na Doença de Parkinson
DOI:
https://doi.org/10.34024/rnc.2006.v14.8763Palavras-chave:
Doença de Parkinson, Qualidade de Vida, Agonistas dopaminérgicos, RevisãoResumo
A doença de Parkinson é uma doença neurodegenerativa em que os sintomas motores predominantes são resultado da morte das células da via nigro-estriatal e conseqüente depleção dopaminérgica no estriado. Os agonistas dopaminérgicos são drogas que atuam diretamente nos receptores de dopamina e sua utilização terapêutica está associada a uma menor freqüência de flutuações motoras em relação ao tratamento com levodopa. O complexo tratamento dessa doença deve ter como um dos objetivos a melhora na qualidade de vida dos pacientes. Os agonistas dopaminérgicos produzem efeito positivo sobre essa variável, possivelmente por diminuírem as complicações do tratamento e possivelmente aliviarem os sintomas depressivos.
Métricas
Referências
Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs Aging 2005; 22: 731-740.
Clarke CE, Guttman M. Dopaine agonist monotherapy in Parkinson’s disease. Lancet 2002; 360:1767-1769.
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Prami- pexole versus levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044–1053.
Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALMPD Study. Parkinson Study Group. Clin Neuropharmacol 2000; 23:34-44.
Whone Al, Watts RI, Stoessl Aj, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003; 54:93-101.
Zadikoff C, Rochon P, Lang A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006; 33:27-33.
De Boer AG, Wijker W, Speelman JD, De Haes JC. Quality of life in patients with Parkinson´s disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996, 61:70-74.
Calne SM, Mak E, Hall J, Fortin MJ, King P, McInnes G, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson´s Impact Scale (PIMS). Parkinsonism Relat Dis 1996; 2:55-61.
Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson´s disease. Qual Life Res 1995; 4: 241-248.
Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. Link- ing clinical variables to health-related quality of life in Parkinson´s disease. Parkinsonism Relat Dis 2002; 8:199-209.
Sławek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson’s disease-a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Dis 2005; 11465-11468.
Happe S, Berger K, FAQT Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson’s disease--a prospective study. J Neurol 2001; 248:1062-1067.
Behari M, Srivastava Ak, Pandey RM. Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Dis 2005;11:221-226.
Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel-group randomized study. J Neurol 2006; 253:601-607.
Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357-360.
Noyes K, Dick AW, Holloway RG, The Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health 2006;9:28-38.
